Acura Pharmaceuticals Inc. (Nasdaq: ACUR) reported that its abuse resistant pain medication failed a mid-stage clinical trial. The stock price fell 37 cents to close at $1.50.
Acura’s Pain Drug Fails Test
August 27, 2013 at 09:42 AM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.